TAME(Targeting Aging with Metformin)は2016年に設計されました。65歳から79歳までの3,000人以上を約6年間追い、メトホルミンが老化にともなう病気――心臓病、がん、認知症、早すぎる死――をまとめて遅らせるかを確かめる試験です。老化そのものが医療の対象になりうることを、規制当局に示す目的もありました。2026年9月の時点で、まだ登録されておらず、参加者も一人もいません。今も資金を探しています。
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512
Keys MT, Thinggaard M, Larsen LA, Pedersen DA, Hjelmborg J, Christensen K. Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study. Int J Epidemiol. 2022;51(6):1886-1898. doi:10.1093/ije/dyac200
Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: a randomized, double-blind, placebo-controlled, multicenter trial: the MASTERS trial. Aging Cell. 2019;18(6):e13039. doi:10.1111/acel.13039
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065. doi:10.1016/j.cmet.2016.05.011
Lakherwal P. Metformin’s aging trial has never enrolled a patient. Longevity Science Daily, 18 September 2026 (ClinicalTrials.gov searched; AFAR’s TAME page). longevitysciencedaily.com
Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192. doi:10.1038/ncomms3192
Strong R, Miller RA, Antebi A, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016;15(5):872-884. doi:10.1111/acel.12496
Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16(11):1165-1173. doi:10.1111/dom.12354
Kulkarni AS, Brutsaert EF, Anghel V, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissue of older adults. Aging Cell. 2018;17(2):e12723. doi:10.1111/acel.12723
Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. doi:10.1111/acel.12880
Wang J, Bi C, Xi H, et al. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1455534. doi:10.3389/fphar.2024.1455534
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Berberine. National Institute of Diabetes and Digestive and Kidney Diseases; updated 6 October 2020. NCBI Bookshelf NBK564659
Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-572. doi:10.1007/s00228-005-0952-3